SPARC Partner Ocuvex Receives FDA CRL for PDP-716

SPARC's licensing partner Ocuvex Therapeutics received a Complete Response Letter from the US FDA for its PDP-716 New Drug Application.
The FDA's CRL was issued solely due to inspection findings at the finished product manufacturing facility.
The FDA did not identify any other issues with the PDP-716 NDA submission in its response.
SPARC submitted this material information to exchanges under SEBI Listing Regulations.